<DOC>
	<DOCNO>NCT00987246</DOCNO>
	<brief_summary>The purpose study investigate efficacy LAS41005 comparison placebo LAS106521 actinic keratosis ( AK ) .</brief_summary>
	<brief_title>Study Efficacy LAS41005 Treatment Actinic Keratosis</brief_title>
	<detailed_description>To investigate primary objective : - Superiority placebo non-inferiority LAS106521 measure histological clearance one predefined target lesion ; To investigate secondary objective : - Superiority LAS106521 - Improvement treat lesion ( lesion response ) - Assessment tolerability safety physician global assessment score ( PGA , PGT ) - Patient 's assessment tolerability efficacy patient 's compliance</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Main Have least 4 10 clinically confirm AK target lesion mild moderate intensity within face/forehead bald scalp ( exclude eyelid , lip , mucosa ) , i.e . actinic keratosis grade I II accord Olsen EA et al . 1991 Woman childbearing potential allow participate study use highly effective method contraception Main Have receive effective treatment AK three month precede clinical trial Have know hypersensitivity LAS41005 LAS106521 Have currently malignant benign tumor skin within treatment area ( e.g . malignant melanoma , basal cell carcinoma , squamous cell carcinoma ) Patient 's take phenytoin Show cornu cutaneum like alteration skin face bald scalp ( target area )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>AK</keyword>
	<keyword>NMSC</keyword>
	<keyword>Combination</keyword>
</DOC>